The Paradox Nobody Warns You About
Every expansion story starts the same way. A health system breaks ground on a new cancer center, or adds a wing of infusion chairs, or brings a linear accelerator online. There is a ribbon-cutting. There is a press release about expanded access to care. Somewhere, a capital budget that took years to approve finally becomes a building full of nurses, pharmacists, and patients.
That story is true, and it matters. But it is not the whole story. On the same day the doors open, a second story starts – one that does not show up in the groundbreaking photos and rarely reaches the board deck until months later, when someone finally asks why net collections did not grow the way patient volume did.
The honest answer is usually not fraud, negligence, or a single bad decision. It is something quieter and more structural: a health system can do almost everything right operationally – build the capacity, hire the clinicians, treat more patients – and still lose a meaningful share of the revenue that expansion was supposed to generate, simply because the revenue cycle was not built for the volume and complexity that arrived with it.
We call that pattern the denial curve. Picture two lines on a chart. One tracks patient volume, or claim volume, climbing after an expansion – exactly as planned. The second tracks denied claims. In a revenue cycle built for its current scale, that second line stays low and flat as the first one rises. In a growing cancer center, it doesn’t. It climbs right behind the first line, and in the worst cases, it climbs faster.
This Isn’t an Isolated Story – It’s the Industry
If any of that sounds familiar, it is worth saying plainly: this is not a sign that your organization is uniquely disorganized. It is the national trend line right now, across specialties, and it is getting worse, not better.
| Figure | What it means | Source |
|---|---|---|
| 41% | of providers report that at least 1 in 10 claims is now denied | Experian Health, State of Claims 2025 |
| 54% | of providers say claim denial rates are increasing year over year | Experian Health, State of Claims 2025 |
| 95% | of physicians say prior authorization delays access to necessary care | AMA Prior Authorization Physician Survey, 2025 |
| 79% | of physicians report patients abandon treatment because of authorization obstacles | AMA Prior Authorization Physician Survey, 2025 |
| 74% | of physicians say denials have increased over the past five years | AMA Prior Authorization Physician Survey, 2025 |
| Just 14% | of providers have actually implemented AI tools in their claims process, versus payers scaling AI review broadly | AJMC, 2025–2026 claims/AI survey coverage |
| 90% | of denied claims still require human review before they can be resubmitted | AJMC, 2025–2026 claims/AI survey coverage |
Two figures from that table are worth sitting with. First, missing or inaccurate data and authorization issues are consistently the leading causes of denials nationally – which means the fix, more often than not, has to start upstream of coding, at intake and eligibility. Second, the gap between how much providers believe automation could help (67% say AI can improve the claims process) and how many have actually deployed it (14%) is enormous. That gap is not a curiosity. It is a structural disadvantage, because payers are not waiting on the other side of it.
Why Expansion Multiplies the Risk
The link between growth and denials is not bad luck. It follows directly from how oncology and specialty-drug billing works, and it is worth reasoning through step by step, because the same logic tells you where the fix has to happen.
First, there is a volume shock rather than a volume ramp. A new infusion suite does not build its patient census gradually over a year, referral patterns and physician recruitment often mean J-code and specialty-drug claim volume jumps within weeks of opening. Whatever authorization and coding workflow handled the old, smaller volume is immediately asked to handle a larger, more complex one, with no transition period.
Second, oncology concentrates dollar risk into single claims in a way most specialties do not. A missed prior authorization for a routine office visit might cost a practice a few hundred dollars. A missed prior authorization for a biologic or chemotherapy agent that runs five figures per dose is a single, large, often unrecoverable loss. That means the tolerance for error has to be near-zero at precisely the moment volume and complexity make errors more likely.
Third, the rules themselves are not static. Payer medical-necessity criteria, prior-authorization thresholds, and reimbursement methodology for specialty drugs shift quarter to quarter – sometimes payer by payer. A workflow tuned to last year’s rules will misfire against this year’s claims even if nothing about the hospital’s own process has changed.
Fourth, and most simply: capital planning and revenue cycle planning usually happen on different timelines. Boards approve a cancer center years in advance, the billing, authorization, and denial-management capacity to support it is rarely built out on the same schedule. The result is predictable, not mysterious – which is also the good news, because a predictable problem can be planned for.
Three Forces Making This Harder in 2026 Than It Used to Be
1. Prior authorization keeps expanding, not shrinking
In 2025, major insurers publicly pledged to streamline prior authorization. According to the American Medical Association’s most recent physician survey, most physicians are not convinced it is working: only 33% believe the pledge will lead to meaningful improvement. Meanwhile, 95% say prior authorization delays necessary care, 79% report patients abandoning treatment because of authorization obstacles, and 74% have watched denials rise over the past five years. For a program planning an expansion, the planning assumption has to be that this burden will still be climbing when the doors open – not easing.
2. Payers are automating denials faster than providers can respond
The claims fight is no longer evenly matched. Only 14% of providers report having implemented AI tools in their own claims process, even though two-thirds believe such tools could help. On the other side of the transaction, payers have moved aggressively toward automated claim review, which is a meaningful part of why 41% of providers now see denial rates of 10% or higher, and why 90% of denied claims still require manual human review before they can even be resubmitted. A revenue cycle built around a person reading each remittance line by line is competing against a system built to deny at scale.
3. The workforce meant to catch it all is stretched and turning over
Patient access and coding roles – the exact positions responsible for catching an authorization gap or a coding error before a claim goes out – have been among the hardest in healthcare to keep staffed. Health systems report losing experienced billing staff to better-paying opportunities, sometimes outside healthcare entirely, and struggling to backfill specialty-specific expertise quickly. Some organizations have responded with robotic process automation for routine tasks, at least one health system profiled by HFMA went as far as outsourcing an entire 100-person revenue cycle department rather than continue competing for scarce talent. The pattern across these responses is telling: none of them was simply “hire more people and wait.”
Why “Just Hire More People” Doesn’t Flatten the Curve
When denials spike after an expansion, the instinctive response is to add billing staff. It is an understandable instinct, and it is usually the wrong first move – not because more capacity is bad, but because it treats a specialization problem as if it were only a headcount problem.
Consider the timeline mismatch alone. Recruiting, hiring, and training a biller who genuinely understands J-code reimbursement, buy-and-bill economics, and payer-specific medical-necessity criteria takes months. The volume shock from an expansion arrives in weeks. By the time new hires are fully productive, a large share of the early claims that were mishandled are already outside the timely-filing window – permanently uncollectable rather than merely delayed.
Then there is the wage-competition problem documented across the industry: hospitals are frequently unable to out-bid the broader market for the patient-access and coding talent they need, which means the roles most under strain are also the hardest to fill. And even where headcount can be added, a generalist medical biller does not automatically bring oncology-specific expertise – the difference between billing a routine office visit and billing a five-figure specialty infusion is not a matter of working harder, it is a matter of knowing a different rule set.
This is why the health systems that have handled this well typically did not solve it with headcount alone. They paired their teams with automation, specialized expertise, or a dedicated partner – because the actual constraint was never the number of hours available. It was whether the hours being spent were backed by oncology- and payer-specific knowledge, applied before a claim went out the door rather than after it came back denied.
What Actually Works: Capture, Authorize, Collect
Flattening the denial curve is less about any single fix and more about a discipline applied consistently at three points in the revenue cycle – whether that discipline lives with an internal team, a specialized partner, or both working together.
Capture
Because missing or inaccurate data is consistently the single leading cause of denials nationally, the work has to start before a claim is ever coded – at registration, insurance verification, and benefit investigation. For oncology specifically, that means confirming coordination of benefits, verifying whether a specialty drug routes through the medical or pharmacy benefit, and catching gaps at intake rather than at the remittance stage, when they are far more expensive to fix.
Authorize
This is where the highest-dollar risk sits, and it has to be proactive rather than reactive: every prior-authorization requirement identified and cleared before the drug is administered, not after, and every claim coded against each payer’s current rules – not the rules that applied six months earlier. Given how often those rules change, this step alone requires ongoing, payer-specific monitoring that a generalist workflow rarely sustains.
Collect
A denial is not a dead end if it is worked immediately, it becomes one if it is allowed to age past the payer’s timely-filing window. Active, prioritized denial work-down – not a quarterly batch review – is what determines whether a denied claim becomes a delayed payment or a permanent write-off.
None of this requires dismantling an existing team or rebuilding a hospital’s billing system from scratch. It requires oncology- and payer-specific expertise applied at exactly the volume and speed the expansion demands – which is precisely the gap a specialized revenue cycle partner is built to close, and the reason Health First Technologies exists.
A Diagnostic: Is Your Revenue Cycle Ready for Growth?
Whether an expansion is already open or still on the drawing board, the following questions tend to surface the gap before it shows up in a denial report. Most growing cancer centers will recognize several of these – that is not a verdict on the team, it is a signal about where to look first.
- Has your denial rate risen since your last service-line expansion, and can you say by how much?
- Do you track prior-authorization-related denials separately from coding-related denials, or do they blur together in one bucket?
- Do you know your average time-to-resolution for a denied specialty-drug claim – and how many age past the timely-filing window before anyone works them?
- Is your billing team specifically trained on J-code and buy-and-bill reimbursement, or is it applying general medical-billing knowledge to a specialty case mix?
- When a payer updates its prior-authorization or medical-necessity criteria, how long does it take before that change reaches the person submitting your claims?
- Have you lost billing or patient-access staff in the last twelve months – and did specialty-specific knowledge leave with them?
- Can your current systems flag a missing prior authorization before a drug is administered, or only after the claim comes back denied?
- Do net collections as a percentage of charges look the same today as they did before your last expansion?
- Does leadership see denial trends in the same meeting as capital and volume metrics, or in a separate report that arrives weeks later?
- If your CFO asked how much of this expansion’s revenue you actually kept, could you answer with confidence today?
If several of these gave you pause, that puts you in the majority of growing oncology programs right now – not the exception.
The Bottom Line
Capital builds capacity. It does not, by itself, build the revenue cycle that turns that capacity into margin. Those are two different investments, on two different timelines, and treating them as one is the quiet cause behind most of the denial curves we see.
The reassuring part of everything above is that this problem is well understood, largely predictable, and addressable without a reorganization. Denial rates rise for identifiable reasons – data gaps at intake, authorization workflows that were not built for the new volume, coding that has not caught up with current payer rules, and a workforce stretched thinner than the case mix now requires. Each of those has a direct, practical answer.
If your organization is opening or expanding a cancer center, infusion suite, or specialty-drug program this year, the highest-leverage moment to act is before volume hits, not after the first wave of denials arrives. iRapidO Global works alongside hospital and health-system revenue cycle teams to pressure-test exactly this – prior authorization coverage, J-code and specialty-drug coding accuracy, and denial work-down – so that the growth story your organization tells stays a growth story all the way through to the bank.
About iRapidO Global
iRapidO Global partners with hospitals and health systems that are opening or expanding specially cancer care, infusion, and specialty-drug programs, focused specifically on the revenue cycle pressure points that come with that growth: prior authorization, J-code and specialty-drug coding, and denial management. The goal in every engagement is the same – no new headcount and no rebuilt workflows for your team, just the reimbursement your organization has already earned, fully captured, so your clinical staff can stay focused on patients.
Figures cited reflect the most recently published data available from each source as of August 2026 and are provided for general informational purposes. This article does not make guarantees about specific financial outcomes for any organization.
